Mostrar el registro sencillo del ítem

dc.contributor.author
Perroud, Herman Andrés  
dc.contributor.author
Alasino, Carlos M  
dc.contributor.author
Rico, Maria Jose  
dc.contributor.author
Queralt, Francisco  
dc.contributor.author
Pezzotto, Stella Maris  
dc.contributor.author
Rozados, Viviana Rosa  
dc.contributor.author
Scharovsky, Olga Graciela  
dc.date.available
2018-07-27T18:18:38Z  
dc.date.issued
2016-05  
dc.identifier.citation
Perroud, Herman Andrés; Alasino, Carlos M; Rico, Maria Jose; Queralt, Francisco; Pezzotto, Stella Maris; et al.; Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy; Future Medicine; Future Oncology; 12; 10; 5-2016; 1233-1242  
dc.identifier.issn
1479-6694  
dc.identifier.uri
http://hdl.handle.net/11336/53320  
dc.description.abstract
Aim: The objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib. Material & methods: Patients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET). Results: A total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional well-being and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it. Conclusion: Patients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Future Medicine  
dc.rights
info:eu-repo/semantics/openAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
Breast Cancer  
dc.subject
Brief Pain Inventory  
dc.subject
Celecoxib  
dc.subject
Cyclophosphamide  
dc.subject
Ecog  
dc.subject
Fact-B  
dc.subject
Metronomic Chemotherapy  
dc.subject
Quality of Life  
dc.subject.classification
Medicina Critica y de Emergencia  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2018-07-17T14:05:15Z  
dc.journal.volume
12  
dc.journal.number
10  
dc.journal.pagination
1233-1242  
dc.journal.pais
Reino Unido  
dc.journal.ciudad
Londres  
dc.description.fil
Fil: Perroud, Herman Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina  
dc.description.fil
Fil: Alasino, Carlos M. Instituto de Oncología de Rosario; Argentina  
dc.description.fil
Fil: Rico, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina  
dc.description.fil
Fil: Queralt, Francisco. Instituto de Oncología de Rosario; Argentina  
dc.description.fil
Fil: Pezzotto, Stella Maris. Consejo de Investigación de la Universidad Nacional de Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología; Argentina  
dc.description.fil
Fil: Rozados, Viviana Rosa. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina  
dc.description.fil
Fil: Scharovsky, Olga Graciela. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Consejo de Investigación de la Universidad Nacional de Rosario; Argentina  
dc.journal.title
Future Oncology  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.2217/fon-2016-0075  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.futuremedicine.com/doi/10.2217/fon-2016-0075